Final Results

Final Results Tue, Feb 10, 2026 08:00 CET Report this content 10 February 2026 AstraZeneca results: FY and Q4 2025 Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period Revenue and EPS summary FY 2025 % Change Q4 2025 % Change $m Actual CER 1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue 2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4 2 Reported EPS ($) 6.60 45 43 1.50 55 47 Core 3 EPS ($) 9.16 12 11 2.12 1 (2) Key performance elements for FY 2025 (Growth numbers at constant exchange rates) * Total Revenue up 8% to $58,739m, driven by Oncology, CVRM, R&I and Rare Disease * Growth in Total Revenue across all major geographic regions * Core Operating profit increased 9% * Core EPS increased 11% to $9.16 * Second interim dividend declared of $2.17 per share (159.5 pence, 19.49 SEK). Total dividend declared for FY 2025 increased by 3% to $3.20 per share * 16 positive Phase 3 readouts and 43 approvals in major regions in the last twelve months Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines. The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year. We have more than 100 Phase 3 studies ongoing, including a substantial and growing number of trials of our transformative technologies which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030. Lastly, ordinary shares in our company began trading on the NYSE on the 2nd February, resulting in a harmonised listing structure across exchanges in London, New York and Stockholm, enabling more shareholders to participate in our company's exciting future." Guidance AstraZeneca issues Total Revenue and Core EPS guidance 4 for FY 2026 at CER, based on the average foreign exchange rates through 2025. Total Revenue is expected to increase by a mid-to - high single-digit percentage Core EPS is expected to increase by a low double-digit percentage The Core Tax rate is expected to be between 18-22% If foreign exchange rates for February 2026 to December 2026 were to remain at the average rates seen in January 2026, it is anticipated that Total Revenue in FY 2026 would benefit from a low single-digit percentage positive impact compared to the performance at CER, and Core EPS growth would be broadly similar to the growth at CER. http://www.rns-pdf.londonstockexchange.com/rns/3227S_1-2026-2-9.pdf Results highlights Table 1 : Milestones achieved since the prior results announcement Phase III and other registrational data readouts Medicine Trial Indication Event ceralasertib + Imfinzi LATIFY Post-IO NSCLC Primary endpoint not met baxdrostat BaxAsia Treatment resistant hypertension Primary endpoint met Regulatory approvals Medicine Trial Indication Region Enhertu DESTINY-Gastric04 2L HER2+ gastric/GEJ cancer EU, CN Enhertu DESTINY-Breast09 1L HER2+ mBC US Enhertu DESTINY-Breast06 CTx naïve HER2-low and -ultralow mBC CN Imfinzi PACIFIC-5 Stage III NSCLC CN Imfinzi MATTERHORN Resectable gastric/GEJ cancer US Imfinzi DUO-E dMMR endometrial cancer CN Wainua NEURO-TTRANSFORM ATTRv-PN CN Fasenra MANDARA EGPA CN Saphnelo TULIP-SC SLE (subcutaneous) EU Koselugo KOMET Adult patients with NF1-PN US Koselugo SPRINKLE Paediatric patients with NF1-PN (granule formulation) EU Soliris NCT03759366 gMG (paediatric patients) CN Regulatory submissions or acceptances* in major regions Medicine Trial Indication Region Datroway TROPION-Breast02 Metastatic TNBC not candidates for IO US, EU, CN Enhertu DESTINY-Breast09 1L HER2+ mBC EU Ultomiris ALXN1210-PNH-323 PNH CN baxdrostat BaxHTN / Bax24 Treatment resistant hypertension US, EU gefurulimab PREVAIL Generalised myasthenia gravis US, EU, CN anselamimab CARES Kappa light chain amyloidosis EU, JP * US, EU and China regulatory submissions denotes filing acceptance Other pipeline updates For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix document in the financial results section of the AstraZeneca investor relations website: www.astrazeneca.com/investor-relations.html . Table 2 : Key elements of financial performance: Q4 2025 For the quarter Reported Change Core Change ended 31 December $m Act CER $m Act CER Product Revenue 15,497 10 8 15,497 10 8 * See Tables 3, 7, 29 and 30 for further details of Product Revenue, Product Sales and Alliance Revenue Collaboration Revenue 6 (99) (99) 6 (99) (99) * See Tables 4 and 31 for details of Collaboration Revenue * In Q4 2024, $815m of Collaboration Revenue was recognised as Lynparza, Beyfortus and Koselugo each achieved a sales-based milestone Total Revenue 15,503 4 2 15,503 4 2 * See Tables 5 and 6 for Total Revenue by Therapy Area and by region Gross Margin (%) 80 -2pp -2pp 80 -2pp -2pp − Cost of sales included a $235m expense in Q4 2025 for royalty buyout expenses relating to Saphnelo and rilvegostomig (see page 5, 'Corporate and business development' for details) * Variations in Gross Margin can be expected between periods due to various factors, including fluctuations in foreign exchange rates, product seasonality and Collaboration Revenue * See 'Reporting changes since FY 2024' on page 6 for the definition of Gross Margin 5 R&D expense 3,862 (17) (19) 3,731 4 3 * Core R&D: 24% of Total Revenue + Accelerated recruitment in ongoing trials + Investments in transformative technologies such as IO bispecifics, cell therapy and antibody drug conjugates + Addition of R&D projects from business development + Positive data readouts for high value pipeline opportunities that have ungated large late-stage trials − Reported R&D expense decreased due to impairment charges in Q4 2024 SG&A expense 5,492 2 - 4,453 4 2 * Core SG&A: 29% of Total Revenue Other operating income and expense 6 100 - 2 101 2 2 Operating Profit 2,978 46 40 4,098 (2) (5) − Operating Profit includes the $235m royalty buyout expensed in Cost of sales (see above) + Reported Operating Profit includes R&D impairment charges in Q4 2024 Operating Margin (%) 19 +6pp +5pp 26 -2pp -2pp Net finance expense 349 (4) (2) 269 (13) (10) − Adjustment of interest on tax and maturity of debt during Q4 2025 Tax rate (%) 11 +1pp +1pp 14 -2pp -2pp * Variations in the tax rate can be expected between periods EPS ($) 1.50 55 47 2.12 1 (2) − Year-on-year comparison reflects the sales-based milestones recognised in Q4 2024 + Reported EPS benefitted from reduction in R&D impairments For monetary values the unit of change is percent. For Gross Margin, Operating Margin and Tax rate, the unit of change is percentage points (pp). In the expense commentary above, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a '+' symbol beside an R&D expense comment indicates that the item increased R&D expenditure relative to the prior year period. Corporate and business development Jacobio Pharma In December 2025, Jacobio Pharma announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of China, while AstraZeneca and Jacobio Pharma will jointly develop and commercialise JAB-23E73 in China. Under the terms of the agreement, Jacobio will receive an upfront payment of $100m, and is eligible for additional development and commercial milestone payments of up to $1.9bn, as well as tiered royalties on net sales achieved outside of China. AstraZeneca will be responsible for all clinical development, regulatory submissions, and commercialisation activities for JAB-23E73 outside of China. Modella AI In Q4 2025, Modella AI was acquired by AstraZeneca. The acquisition will embed Modella AI's multi-modal foundation models and AI agents into AstraZeneca's oncology R&D environment. BMS In Q4 2025, AstraZeneca paid Bristol-Myers Squibb Company (BMS) $170m, expensed in Cost of sales, in exchange for the reduction to zero of all royalties payable on Saphnelo sales ex-US. Royalties on US sales will remain payable at a mid-teens percentage. Compugen In Q4 2025, AstraZeneca paid Compugen Ltd. (Compugen) $65m, expensed in Cost of sales, and agreed a potential additional $25m upon the next milestone payment on BLA acceptance, for a portion of Compugen's existing royalty interest in rilvegostomig. AstraZeneca will pay tiered royalties of up to mid-single digits on future sales. AbelZeta In January 2026, AbelZeta Pharma, Inc. (AbelZeta) announced that AstraZeneca has agreed to acquire AbelZeta's 50% share of the China development and commercialisation rights to C-CAR031, an autologous, Glypican 3 (GPC3)-targeting chimeric antigen receptor T-Cell therapy. Following completion of this agreement, AstraZeneca will have the sole right to develop, manufacture and commercialise C-CAR031 globally. AbelZeta will be entitled to receive up to $630m from AstraZeneca including an upfront payment, and development, regulatory and sales milestone payments for the GPC3 program in China. China investment plans In January 2026, AstraZeneca announced plans to invest $15bn in China through 2030 to expand medicines manufacturing and R&D. These investments build on AstraZeneca's substantial footprint in China, including global strategic R&D centres in Beijing and Shanghai. Listing harmonisation On 2 February 2026, AstraZeneca began trading its ordinary shares on the New York Stock Exchange (NYSE), enabling more US investors to participate in the Company's strong growth. Trading in AstraZeneca ordinary shares is now aligned across the NYSE, the London Stock Exchange and Nasdaq Stockholm under a harmonised listing structure. The prior listing of American Depositary Shares on Nasdaq in the US ceased on 30 January 2026. CSPC In January 2026, AstraZeneca announced a new strategic collaboration agreement with CSPC Pharmaceuticals. AstraZeneca will receive exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, including SYH2082, a long-acting GLP-1R/GIPR agonist progressing into Phase I, and three preclinical programmes. CSPC will receive an upfront payment of $1.2bn and is eligible to receive development and regulatory milestones of up to $3.5bn across all programmes. CSPC will also be eligible for further commercialisation and sales milestones plus tiered royalties. Sustainability highlights For the tenth year, AstraZeneca was recognised by CDP for climate action and water stewardship, receiving an A for Climate and A- for Water Security in 2025. This reflects the Company's significant progress in decarbonising and reducing its environmental footprint. The Sustainable Markets Initiative (SMI) Health Systems Task Force, chaired by AstraZeneca CEO Pascal Soriot, supported the development and launch of PSA 2090 , the world's first global standard to measure and assess the environmental impact of pharmaceutical products through their lifecycle. Reporting calendar The Company intends to publish its Q1 2026 results on 29 April 2026. Conference call A conference call and webcast for investors and analysts will begin today, 10 February 2026, at 11:45 UK time. Details can be accessed via astrazeneca.com . Click on the attached PDF to view the full announcement . This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com .